Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 13/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20052868 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL17455262 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL17472320 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL17455214 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL17455265 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL17455120 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL16114427 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL17455483 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL20052864 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL17455238 | 0.87 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944618-B2 | Inhibiting neurotransmitter reuptake | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160024044-A1 | INHIBITING NEUROTRANSMITTER REUPTAKE | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024044-A1 | INHIBITING NEUROTRANSMITTER REUPTAKE | SLC6A2, SLC18A2, SLC6A4 | SLC6A2 1/4885SLC6A4 3/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.